23.08.2011

AUGUST 23, 2011, MOSCOW – OJSC «VEROPHARM» [RTS:VRPH, MICEX:VFRM] announces preliminary data and operational performance indicators for the first half of 2011 year according to the management accounting.

In H1 2011 sales of Veropharm’s finished goods increased by 18% compared to the same period in 2010, reaching RUR 3,154.8 million. [1]

  • Rx drugs sales amounted to RUR 2,189.4 million in H1 2011, a 16,4% inecrease in comparison with H1 2010. The Rx drugs sales accounted for 69,4% of total finished goods sales.[2]
  • OTC drugs sales amounted to RUR 392.6 million in H1 2011, a 32,2% increase in comparison with H1 2010. The share of OTC drugs sales accounted for 12,5% of total finished goods sales.
  • In H1 2011 traditional drug sales amounted to RUR 13.7 million, which represents 55,1% decrease as compared to H1 2010, and made up 0,4% of total finished goods sales.
Group of non-pharmaceutical products
  • Adhesive bandages and cosmetic products sales came to RUR 559.1 million, a 20,3% increase in comparison with H1 2010. The share of adhesive bandages and cosmetic products in total finished goods sales of the Company was 17,7%.

Veropharm sales as part of the Federal Reimbursement Program (FRP) came to RUR 79,1 million, accounting for 2,5% of the Company’s total finished goods sales.[2]

In H1 2011  sales in Russian Federation provide 97% of the Ñompany’s sales. In H1 2011 exports accounted for 3% of the Company’s total finished goods sales compared to 2% in H1 2010.

Rx drugs segment

Total sales of the five most popular prescription drugs by the results in H1 2011 amounted to RUR 803.1 million, or 36% of sales in the prescription drugs segment and 25% of the Company’s total finished goods sales [2].

The five top-selling Rx drugs in H1 2011 results include:

  • Irunine (Itraconazole; ATC[3] «General anti-infectives systemic»); sales growth in comparison with H1 2011 amounted 98%; 10% of sales in the prescription drugs segment;
  • Cerepro (Holina Alfostserat; ATC «Central nervous system»); sales growth in comparison with H1 2011 amounted 42%; 9% of sales in the prescription drugs segment;
  • Geptor (Ademetionine; ATC«Digestive tract and metabolism»); sales growth in comparison with H1 2011 amounted 57%; 7% of sales in the prescription drugs segment;
  • Amigrenin (Sumatriptan; ATC «Central nervous system»); sales growth in comparison with H1 2011 amounted 138%;  5% of sales in the prescription drugs segment;
  • Paclitaxel-LENS (Paclitaxel; ATC «Antineoplastic and immunomodulating agents»); sales growth in comparison with H1 2011 amounted 8%;  5% of sales in the prescription drugs segment;
OTC drugs segment

Total sales of the five products in the OTC drugs segment amounted to 99% of sales in the OTC drugs segment.

  • Xilen (Xylometazoline; ATC «Respiratory system»); sales growth in comparison with H1 2011 amounted 35%; 49% of sales in the OTC drugs segment;
  • Slabilen (Sodium picosulfate;  ATC «Alimentary tract and metabolism»); sales growth in comparison with H1 2011 amounted 34%;  30% of sales in the OTC drugs segment;
  • Motilak (Domperidone; ATC «Alimentary tract and metabolism»); sales growth in comparison with H1 2011 amounted 18%; 15% of sales in the OTC drugs segment;
  • Vitasharm and Vitatress (ATC «Vitamins»); sales growth in comparison with H1 2011 amounted 271%; 4% of sales in the OTC drugs segment;
  • Ginecotex vaginal tablets (Benzalkonium chloride; ATC «Urinary system&sex hormone»); 1% of sales in the OTC drugs segment.
Traditional drugs segment

Total sales of the five most popular traditional  drugs by the results in H1 2011 amounted to RUR 13,4 million, or 97% of sales in the traditional drugs segment.

  • Vero-Dexamethasone (Dexamethasone; ATC «Hormonal drugs»); 57% of sales in the traditional drugs segment;
  • Pyridoxine  hydrochloride (Pyridoxine; ATC «Alimentary tract and metabolism»); 24% of sales in the traditional drugs segment;
  • Fluconazole (Fluconazole; ATC «General anti-infective systemic»); 11% of sales in the traditional drugs segment;
  • Vero-Ciprofloxacin (Ciprofloxacin; ATC «General anti-infective systemic»); 3% of sales in the traditional drugs segment;
  • Vero-Loperamide (Loperamide; ATC «Alimentary tract and metabolism»); 2% of sales in the traditional drugs segment.
Adhesive bandages and cosmetic products segment

In H1 2011 segment of Adhesive bandages and Cosmetic products had the following structure:

  • Conventional bacterial adhesive bandages; 46% of sales in segment in H1 2011;
  • Conventional reel adhesive bandages; 25% of sales in the segment in H1 2011;
  • Therapeutic patches — pepper plasters, 12% of sales in the segment in H1 2011;
  • Therapeutic patches — corn plasters, 16% of sales in the segment in H1 2011;
  • Cosmetic products (Veromistin Silver, Daily, Flores); 1% of sales in the segment in H1 2011.

During the first half of 2011 Veropharm launched production and sales of the following new drugs:

  • Vero-Netilmicin (Netilmicin; ATC «Antiinfectives for systemic use»);
  • Vero-Asparaginase (Asparaginase; ÀÒÑ «Antineoplastic and immunomodulating agents»); new dosage – 10 000 ME ¹ 10;
  • Veroklast (Zoledronic acid; ATC «Musculoskeletal system»); new dosage – 4mg/5 ml 5ml ¹ 1;
  • Veromistin Silver (Myramistin; Remedy for intimate hygiene); new dosage – 50ml ¹ 1;
  • Veromistin Daily (Myramistin; Remedy for hygienic treatment of the skin of hands and feet); new dosage – 50ml ¹ 1;
  • Veromistin Flores (Myramistin; Remedy for oral hygiene); new dosage – 50ml ¹ 1.

In the first half of 2011 received registration certificate for the following products:

  • The bandage Uniplast ointment;
  • The bandage Uniplast wound sorbent;

Additionally, 14 drugs are currently at different stages of the registration process.

At the end of 1H 2011 Veropharm’s debt came to RUR 762.7 million, that represents less than 20% of net assets.

[1]  according to management accounts of OJSC “Veropharm”

[2]  % — percent of finished goods sales

[3]  ATC – anatomico-therapeutico-chemical group.